BOSTON--(BUSINESS WIRE)--Stealth Peptides Inc. (Stealth), a privately held biopharmaceutical company developing innovative mitochondrial therapies for cardiovascular disease and its complications, announced today positive oral Bendavia™ clinical results. The Phase I clinical trial demonstrated that oral Bendavia achieved plasma concentrations shown to be cardioprotective in multiple models of acute and chronic cardiac diseases including heart failure. Bendavia is a compound that targets mitochondria to restore bioenergetics and organ function in cardiovascular and metabolic diseases.
